Chugai Pharmaceutical Co (MEX:4519N) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:4519N Chugai Pharmaceutical Co Ltd MEX:4519N
97 GF Score
Price MXN825.61
GF Value MXN873.09
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

MEX:4519N
97GF Score
Chugai Pharmaceutical Co Ltd MEX:4519N
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Chugai Pharmaceutical Co (MEX:4519N) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of MXN825.61 is trading 5.4% below its estimated GF Value™ of MXN873.09.

Key valuation signals for MEX:4519N:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: MXN873.09 vs. price of MXN825.61 (5.4% below fair value)
  • GF Score™: 97/100 with 1 warning sign

No single metric tells the full story. See the MEX:4519N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
97GF Score

Get the complete analysis for MEX:4519N

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN825.61
Price
MXN873.09
GF Value